|Bid||50.51 x 1100|
|Ask||52.55 x 900|
|Day's Range||52.14 - 52.81|
|52 Week Range||41.23 - 52.84|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||21.23|
|Forward Dividend & Yield||1.25 (2.37%)|
|1y Target Est||53.90|
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle.Source: joreks / Shutterstock.com The reason behind the upcoming legal battle has to do with Victoza. This is Novo Nordisk's (NYSE:NVO) drug for treating diabetes. Mylan (NASDAQ:MYL) is looking to market its own generic version of the drug, which is where the rub comes from.Novo Nordisk is seeking to block any efforts by Mylan to market its generic version of Victoza. Having a generic version of the drug available would eat into the revenue the company would make from selling its name brand version.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovo Nordisk is also seeking to protect its products that still have patent protection. The patents surrounding Victoza will start expiring in July 2021 and the last one will reach its expiration date in March 2033, reports BioSpace.Novo Nordisk suing Mylan specifically has to do with this new drug from the latter being an alleged illegal generic of its own. The company is filing this lawsuit in response to an abbreviated new drug application filed by Mylan with the U.S. Food & Drug Administration. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The lawsuit from Novo Nordisk against Mylan was filed on Monday. This had the company filing its lawsuit with the U.S. District Court for the District of Delaware. Lawsuits can be lengthy procedures, so it will likely be some time before we see the outcome of this one.NVO stock was up 1% and MYL stock was down slightly as of Thursday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip As of this writing, William White did not hold a position in any of the aforementioned securities.The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.
Novo Nordisk (NVO) receives EC approval for its fast-acting insulin aspart, Fiasp, for the treatment of diabetes in adolescents and children aged one year or older.
Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement. "Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish crowns ($1.75 billion) based on trading of Novo shares for two years from February 2015.
BOSTON, Aug. 14, 2019 /PRNewswire/ -- Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where companies develop truly transformational science. Novo Nordisk, a global healthcare company committed to discovering, creating and co-creating innovation to solve healthcare challenges for people living with diabetes and other serious chronic diseases, issues an open call for promising start-up companies to submit non-confidential proposals for a Novo Nordisk-sponsored LabCentral "Golden Ticket." The winner will have the chance to receive access for one scientist and one bench at LabCentral's state-of-the-art shared lab space in Boston for research for one year.
When Boston University professor Ed Damiano set out to raise a new tranche of funding for a startup last year, his hopes were low: Diabetes device makers were struggling to raise money in a field that was being increasingly dominated by two players.
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Novo Nordisk raised its sales forecast for this year thanks to growing demand for obesity drugs and a new injectable treatment for diabetes, now its growth engine as insulin sales decline. The Danish company is pinning its hopes on a relatively new treatment for type 2 diabetes as its older insulin drugs face political pressure over the soaring cost of the life-sustaining medicine in the United States. Sales of its new once-weekly injectable treatment, branded Ozempic, rose to 2.3 billion Danish crowns ($345 million) in the second quarter, which was higher than expected by analysts, sending shares in the world's top diabetes drugmaker 1.4% higher in early trading on Friday.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...
Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes. The tablet version of its diabetes drug, known as semaglutide, is an important growth prospect for the Danish drugmaker, which faces pressure on prices from competitors and U.S. lawmakers who have been critical of rising drug costs. Novo, the world's biggest producer of diabetes drugs, said the new plant near Durham would receive shipments of the active pharmaceutical ingredient needed to produce the pill from another factory under construction in North Carolina.
Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.